Notably, blockade of PAI-1 was shown to reduce PD-L1 expression, restore cytotoxic T cell activity, and promote tumor regression in preclinical models, underscoring its potential as a therapeutic target [52]. The gene discussed is SERPINE1; the disease is neoplasm.